Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355497 · ClinicalTrials.gov registry record · Phase 3
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
A Phase 3 study, sponsored by GTx.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT01355497 is a Phase 3 study that has completed, run by GTx. The registered enrollment target is 330 participants.
The verdict
NCT01355497, a Phase 3 study, has completed, sponsored by GTx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
Interventions
- DRUG placebo
- DRUG GTx-024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01355497
The ClinicalTrials.gov registry entry for NCT01355497 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GTx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01355497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01355497 about?
NCT01355497 is a clinical study titled "Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum". The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
What is the current status of trial NCT01355497?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2011-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01355497?
The interventions under investigation include: placebo (DRUG), GTx-024 (DRUG).
Who is sponsoring clinical trial NCT01355497?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.